Mereo Biopharma

Mereo BioPharma is a clinical-stage biopharmaceutical company that focuses on acquiring, developing, and commercializing therapeutics for rare diseases and oncology. Founded in March 2015 by Dr. Denise Scots-Knight, Alastair MacKinnon, Charles Sermon, and John Richard, the company is headquartered in London, UK. The founders, including CEO Dr. Scots-Knight, came from Phase4 Partners, a venture capital firm with a background in life sciences investment that was spun out of Nomura. Their strategy was to acquire promising clinical-stage drug candidates from large pharmaceutical companies, bypassing the high-risk, early-stage discovery phase.

Mereo launched with significant initial funding of $119 million (£76.5 million) and a portfolio of three clinical-stage candidates acquired from Novartis, which in turn took an equity stake in Mereo. The company has since expanded its pipeline, which includes candidates for osteogenesis imperfecta (OI) and alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Its primary product candidates are setrusumab for OI and alvelestat for AATD. It also has two oncology candidates, etigilimab (anti-TIGIT) and navicixizumab.

The company's business model is centered on R&D investment and strategic collaborations. Revenue is generated through upfront payments, milestone payments based on development progress, and potential future royalties from licensing agreements with partners like Ultragenyx, Feng Biosciences, and ReproNovo SA. For example, the partnership with Ultragenyx for setrusumab includes potential milestone payments and royalties, while Mereo retains commercial rights in the EU and UK. The company listed on NASDAQ in April 2019 after merging with OncoMed.

Keywords: rare disease therapeutics, oncology, clinical-stage biopharmaceutical, drug development, orphan diseases, setrusumab, alvelestat, etigilimab, osteogenesis imperfecta, AATD, clinical trials, pharmaceutical licensing, biopharma partnerships, TIGIT inhibitor, specialty pharmaceuticals, biologics, small molecules, anti-sclerostin antibody, neutrophil elastase inhibitor, corporate development